Quantcast

Latest Nilotinib Stories

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...

2009-10-20 00:15:00

EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2009-05-28 08:30:00

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL. Quest Diagnostics Incorporated (NYSE: DGX) is the world's leading provider of diagnostic testing, information and...

2008-11-12 12:00:07

CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia. INNO-406 is being evaluated for the treatment of patients with chronic myeloid leukemia (CML) and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to imatinib and second line tyrosine...

2008-11-11 09:00:08

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML). INNO-406 is being evaluated for the treatment of patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+)...

2008-10-08 09:00:12

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in...

2008-08-27 09:00:23

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1)....

2008-06-16 09:01:19

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations. The data presented complement the...

2006-12-06 18:02:44

By ED SUSMAN After five years of treatment nearly 90 percent of leukemia patients treated with Gleevec are still alive -- an outcome barely conceivable before the drug was discovered. The Gleevec story truly is a triumph of science over disease, Brian Druker, the lead investigator of the studies with the anti-cancer drug, told United Press International Wednesday. Druker, professor of medicine at the Oregon Health and Sciences University Cancer Center in Portland, said, The results we...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.